AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Pidantuan

Published November 5, 2026 · Updated November 6, 2026

Therapeutic Potential of Classical Psychedelics and NonHallucinogenic Psychoplastogens ...

Read the full story at Pidantuan

journal：Psychiatry and Clinical Psychopharmacology Authors：Kenji Hashimoto; Feyza Aricioglu; Mesut Cetin Published date：--.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics